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All patients are entitled to equal access to health care re-
sources. The Department of Pharmacoeconomics at Uni-
versity of Texas MD Anderson Cancer Center (UTM-
DACC) administers a Patient Assistance Program (PAP)
that provides assistance to indigent patients with free
pharmaceuticals for their therapy. Drug cost is recovered
through a drug reimbursement program offered by phar-
maceutical companies. OBJECTIVE: The objective of
this report is to examine trends in drug cost savings to in-
digent patients at UTMDACC using the PAP model.
METHODS: A retrospective study using data from Sep-
tember 1996 to August 2000 was conducted to determine
the value of the program. Patients were enrolled in this
program if they qualified based on the Financial Classifi-
cation Scale. Uninsured patients as well as under-insured
patients were considered in this study. Data was analyzed
to evaluate the trend in cost savings for the three fiscal
years. RESULTS: Over $334 million was spent on drug
cost over the period. There was an average increase of
22% per year in drug cost. The indigent patients ac-
counted for 9% of the total patient population at UTM-
DACC. An estimated $33 million was spent on drugs for
indigent patients during that period. The PAP system re-
covered a total of $16.8 million; $4.1M (1997), $4.3M
(1998), $3.5M (1999), and $4.9M (2000). This accounts
for 51% in drug cost recovery through this program. The
fluctuation in cost saving was attributed to changes in the
number of programs, number of patients enrolled, and
product mix. CONCLUSION: The PAP system has pro-
vided free drugs to patients without financial resources
and reduced the economic burden of this population on
the health care institution. The program has created
goodwill between the pharmaceutical companies, the
health care institution, the patients and the community.
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OBJECTIVE: To share lessons learned from developing a
reliable and valid questionnaire for adequacy of sedation
in pharmacologically paralyzed critically ill patients.
METHODS: In phase 1, seven experts listed 21 charac-
teristics describing anxiety in pharmacologically para-
lyzed patients. In phase 2, two scenarios were created il-
lustrating the experience of paralysis: one with and one
without receiving a sedative. A convenience sample of 30
people evaluated scenarios to determine the importance
of characteristics obtained from phase 1 using a five-
point scale. Items were reduced to the 10 most important
characteristics (mean 
3). Based on these results, the fi-
nal instrument consisted of 12 questions: 2 categorical
addressing memory of the experience and 10 referred to
characteristics of anxiety. In phase 3, two groups of criti-
cally ill patients were administered the questionnaire: 1)
sedated only and 2) sedated and pharmacologically para-
lyzed. The questionnaire was administered twice for reli-
ability. Questionnaire results were compared to subjec-
tive and objective sedation monitoring tools for validity.
Calculated sample size was 20 for each group. RESULTS:
During six months, 21 patients consented to participate.
Twelve patients died and nine patients (6 sedated, 3 se-
dated/paralyzed) were administered questionnaires. Five
patients (3 sedated, 2 sedated/paralyzed) did not remem-
ber the intensive care unit experience. Two of three pa-
tients in the sedated group who answered the question-
naire found it difficult to remember over time. One
sedated/paralyzed patient who answered the question-
naire received a sedative without amnesic properties and
felt anxious during therapy. The distressful feeling of this
patient was comparable to findings of the objective seda-
tion tool. CONCLUSIONS: Mortality in this critically ill
patient population was high. Due to amnestic properties
of sedatives most patients did not remember the experi-
ence. Of patients who remembered, their memory deteri-
orated over time. Based on lessons learned, it may require
2–3 years to achieve the necessary sample size.
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INTRODUCTION: The ERIQA Group aims to create
guidance for European regulatory authorities on the as-
sessment of the quality of HRQL studies in clinical trials
and to evaluate the validity of HRQL claims. OBJEC-
TIVES: To identify disease or drugs in which a formal
HRQL assessment is recommended. To identify measures
and methods recommended. To evaluate the reliability of
recommendations across documents. METHODS: Infor-
mations were searched on the EMEA website (www.
eudra.org/emea.html). A research was performed with
the two key words: “Quality of life” and “QoL”. All the
documents retrieved were reviewed. RESULTS: 133 doc-
uments were retrieved excluding duplicates (129: Quality
of Life, 25: QoL). 19 documents derived from the Effi-
cacy Working Parties (EWP) including nine notes for
guidance (Weight Control, Cancer, Chronic Peripheral
Arterial Occlusive Disease, Cardiac Failure, Stable An-
gina Pectoris, Antiarrythmics, Parkinson, Alzheimer,
Multiple Sclerosis), concept paper (3), points to consider
(5) and position statements (2). Only one document was
a note for guidance for ICH. 104 European Public As-
sessment Report (EPAR) were retrieved, representing 26
products. Nine miscellaneous documents were found in-
